HEARTCARE-B (06609) climbed more than 10%, and as of the time of writing, the stock was up 10.3% to HK$56.75 with a trading volume of HK$13.4465 million.

On the news front, HEARTCARE-B will hold a board meeting today to review and approve the interim results of the company and its subsidiaries for the six months ended June 30, 2025, among other matters.

The company previously announced that it expects to achieve a net profit attributable to shareholders of no less than RMB 40 million for the first half of 2025. The turnaround from loss to profit is primarily attributed to revenue growth driven by increased sales of newly launched hemorrhagic stroke treatment devices, as well as acute ischemic stroke treatment devices and other hemorrhagic stroke treatment devices. Additionally, effective cost control measures for sales costs and administrative expenses have reduced the group's overall expense ratio, while changes in the development stages of the group's R&D projects have led to decreased research and development expenditures. Fair value gains on financial assets measured at fair value through profit or loss have also increased.